Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,816Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M49.9EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)21.9Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %2.0PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M11,600,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IYH

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

IYH is held by these investors:



IYH: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.481551.05view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94823.97view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.1791970.59view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.3611408.82view
Bebek, IvanDirector 2017-01-16Buy8,990$3.384530.77view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4138075.61view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91460.8view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.272396.33view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.38159.22view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.15104246.67view

Quarterly/Annual Reports about IYH:

    News about IYH:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Finally, a draft of Obamacare repeal emerges. It would defund Planned Parenthood Feb 24 2017
    Eli Lilly & Co.’s Revenues in 4Q16 Feb 23 2017
    How to Play Pfizer's Fourth-Quarter Results With ETFs Feb 01 2017
    Why GE’s Healthcare Revenues Rose in 4Q16 Jan 27 2017
    Analyzing Bristol-Myers Squibb’s Other Segments in 4Q16 Jan 25 2017
    How Should Investors Play Healthcare? Jan 24 2017
    3 ETFs to Buy If You're Impressed With Johnson & Johnson's Fourth Quarter Jan 24 2017
    Why health-care stocks aren’t moving after President Trump’s Obamacare executive order Jan 24 2017
    U.S. fund managers betting Trump fails to rewrite Obamacare Jan 24 2017
    What’s Expected from Bristol-Myers Squibb’s 4Q16 Earnings? Jan 23 2017
    Can Q4 Earnings Revitalize Healthcare ETFs? Jan 23 2017
    Will Johnson & Johnson’s Profitability Improve in 4Q16? Jan 23 2017
    A Look Into The Economic And Human Cost Of A Partial Obamacare Repeal Jan 12 2017
    Gilead Sciences’ Liver Disease Drugs Portfolio Jan 02 2017
    What Factors Are Contributing to Gilead Sciences’ Growth? Dec 30 2016
    The Competitive Landscape for Enbrel Dec 29 2016
    What’s Behind Amgen’s Discounted Valuation? Dec 28 2016
    2 Beaten-Down Funds To Buy For 9.4% Dividends, And 3 To Avoid Dec 24 2016
    Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug Dec 21 2016
    Pfizer Has Strong Track Record since 2010 Dec 15 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)